NQO-1 Antibody - BSA Free

Immunocytochemistry/ Immunofluorescence: NQO-1 Antibody [NBP1-31355]

Immunocytochemistry/Immunofluorescence: NQO-1 Antibody [NBP1-31355] - Paraformaldehyde-fixed HeLa, using antibody at 1:200 dilution.

Western Blot: NQO-1 Antibody [NBP1-31355]

Western Blot: NQO-1 Antibody [NBP1-31355] - A. 50 ug mouse heart lysate/extract 12% SDS-PAGE NQO1 antibody [C2C3], C-term dilution: 1:500 The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.

Western Blot: NQO-1 Antibody [NBP1-31355]

Western Blot: NQO-1 Antibody [NBP1-31355] - A. 50 ug rat heart lysate/extract 12% SDS-PAGE NQO1 antibody [C2C3], C-term dilution: 1:500 The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.

Immunohistochemistry-Paraffin: NQO-1 Antibody [NBP1-31355]

Immunohistochemistry-Paraffin: NQO-1 Antibody [NBP1-31355] - Human rectal carcinoma. NQO1 antibody [C2C3], C-term diluted at 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.

Immunohistochemistry-Paraffin: NQO-1 Antibody [NBP1-31355]

Immunohistochemistry-Paraffin: NQO-1 Antibody [NBP1-31355] - Mouse kidney. NQO1 stained by NQO1 antibody [C2C3], C-term diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.

Immunohistochemistry: NQO-1 Antibody [NBP1-31355] -

Immunohistochemistry: NQO-1 Antibody [NBP1-31355] - NQO1 promotesin vivo tumour growth.(a) RKO/pNQO1, RKO/shCont & RKO/pshNQO1 cells injected subcutaneously into right flank of athymic, 7-week-old female BALB/C nude mice, & tumour growth assessed. Tumour volume (TV) calculated by using following formula: TV=length × (width)2 × 0.5. Each group contained 12 animals. (**P<0.01 w/ unpaired t-test). (b) Immunohistochemical analyses of RKO/pNQO1, RKO/shCont, & RKO/pshNQO1 xenograft tumours. The sections stained for NQO1, HIF-1 alpha, proliferation (Ki67) & apoptosis (CC3) using 3,3′-DAB. Scale bar, 50 μm. (c) Quantification of NQO1, proliferative marker Ki67 & apoptotic marker CC3 in RKO/pNQO1, RKO/shCont & RKO/pshNQO1 xenograft tumours (n=3 each group). n=5 in each tumour. Two-tail t-test. **P<0.01, *P<0.05. #, not significant. All error bars represent mean±s.e.m. (d) RKO/pshCont1/pshCont2, RKO/pNQO1/pshCont2 & RKO/pNQO1/pshHIF-1 alpha injected subcutaneously into right flank of athymic, 7-week-old female BALB/C nude mice, & tumour growth assessed. Tumour volume (TV) calculated by using following formula: TV=length × (width)2 × 0.5. Each group contained 10 animals (*P<0.05 w/ unpaired t-test). (e) Immunohistochemical analyses of RKO/pshCont1/pshCont2, RKO/pNQO1/pshCont2 & RKO/pNQO1/pshHIF-1 alpha xenograft tumours for HIF-1 alpha, proliferation (Ki67), apoptosis (CC3) & vasculature (CD34) using 3,3′-DAB. Arrowheads denote blood vessels. Scale bar, 50 μm. (f) RKO/pNQO1/pshCont or RKO/pNQO1/pshHIF-1 alpha xenograft tumours (n=3–5 each group) quantified for proliferation (Ki67), apoptosis (CC3) & vascularization (CD34). n=5 in each tumour. Two tailed t-test. **P<0.01, *P<0.05. #, not significant. All error bars represent mean±s.e.m. (g) Schematic model showing how NQO1 stabilizes HIF-1 alpha in cancer cells. Image collected & cropped by CiteAb from following publication (https://pubmed.ncbi.nlm.nih.gov/27966538), licensed under a CC-BY license. Not internally tested by Novus Biologicals.